A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Hepatocellular Carcinoma (HCC)
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 198 (planned)
- Started
- Mar 16, 2026
- Main results expected
- Oct 15, 2029
- Fully finished
- Oct 14, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with adverse events (AEs)
Measured over: Up to approximately 25 weeks
Number of participants with serious adverse events (SAEs) (as per Common Terminology Criteria for Adverse Events v5 (CTCAE v5))
Measured over: Up to approximately 25 weeks
Number of participants with AEs meeting protocol-defined dose-limiting toxicity (DLT) criteria
Measured over: Up to day 21
Number of participants with AEs leading to discontinuation
Measured over: Up to approximately 25 weeks
Number of participants with AEs leading to death
Measured over: Up to approximately 25 weeks
Objective response (OR) (confirmed complete response (CR) or partial response (PR)) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator assessment
Measured over: Up to week 48
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07291076 · record last updated 2026-10-23 · checked 2026-11-09 15:47 UTC